Sidley represented OrbiMed and RA Capital Management on their investment in Verdiva Bio Limited’s (Verdiva) US$411 million Series A financing, one of, if not the, largest raised by a UK-based biotech to date.
Verdiva is a clinical-stage biopharmaceutical company focused on developing innovative therapies targeting cardiometabolic disorders.
The Sidley team was led by Private Equity partners Robert Darwin (London) and Geoffrey Levin (New York), supported by Pedro Sacadura Botte and Jagata Swaminathan (Private Equity); Patrick Harrison and Edward Sharon (Antitrust and Competition); Teresa Reuter, Eric Kauffman, Peter McCorkell, and Alex Down (Labor, Employment and Immigration); Rachel Kleinberg (Tax); Nicholas Frey (Employee Benefits and Executive Compensation); and Istvan Hajdu (Capital Markets).
